Schedule 13D ownership disclosure
Compass Therapeutics Inc
COMMON STOCK · CUSIP: 20454B104
Event date: 2025-08-13
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- ORBIMED ADVISORS LLCReported CIK 0001055951
Shares: 15,219,994.00 · Class: 8.9%
- ORBIMED CAPITAL GP V LLCReported CIK 0001615374
Shares: 15,219,994.00 · Class: 8.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000947871-25-000785
- Form type
- SCHEDULE 13D/A
- Filer
- Compass Therapeutics, Inc.
- CIK
- CIK 1738021
- Filed
- Aug 15, 2025
- Reporting period
- Aug 13, 2025
- Description
- Schedule 13D beneficial ownership